Lilly’s weight-loss drug cuts diabetes risk by 94% in three-year trial, company says

Lilly’s weight-loss drug cuts diabetes risk by 94% in three-year trial, company says

Eli Lilly’s weight-loss drug cut the risk of developing type 2 diabetes by 94% in prediabetic adults who were overweight or obese after three years of weekly injections, the company disclosed in a statement on Tuesday.  NBC News Health

​Eli Lilly’s weight-loss drug cut the risk of developing type 2 diabetes by 94% in prediabetic adults who were overweight or obese after three years of weekly injections, the company disclosed in a statement on Tuesday. 

Leave a Reply

Your email address will not be published. Required fields are marked *